Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
418
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

Amer M. Zeidana Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USACorrespondence[email protected]
View further author information
,
Cynthia Z. Qib Analysis Group, Inc., Boston, MA, USAView further author information
,
Hongbo Yangb Analysis Group, Inc., Boston, MA, USAView further author information
,
Andy Garnhamc Astellas Pharma, Inc., Northbrook, IL, USAView further author information
,
Manasee V. Shahc Astellas Pharma, Inc., Northbrook, IL, USAView further author information
&
Bhavik J. Pandyac Astellas Pharma, Inc., Northbrook, IL, USAView further author information
Pages 762-764 | Received 24 Sep 2021, Accepted 26 Oct 2021, Published online: 08 Nov 2021

References

  • Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
  • FröHling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group ulm. Blood. 2002;100(13):4372–4380.
  • Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695.
  • Mangan JK, Luger SM. Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol. 2011;2(2):73–82.
  • Xu J, Lv TT, Zhou XF, et al. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study. Medicine. 2018;97(39):e12102.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
  • Armistead PM, de Lima M, Pierce S, et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009;15(11):1431–1438.
  • United States Food and Drug Administration. Highlights of prescribing information: XOSPATA (gilteritinib) [Internet]. Silver Spring (MD): USFDA; 2018 [cited 2021 May 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf
  • Medeiros BC. Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res. 2018;68:32–39.
  • Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411.
  • Tremblay G, Westley T, Garib S, et al. Indirect number needed to treat: comparative effectiveness of glasdegib + low-dose cytarabine vs azacitidine or decitabine in acute myeloid leukemia patients ineligible for intensive chemotherapy: PS1045. Hemasphere. 2019;3(S1):472–473.
  • Ritchie EK, Cella D, Fabbiano F, et al. The relationship between hospitalization and patient-reported outcomes (PROs) in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (r/r) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL study. Blood. 2019;134(1):1332.
  • Ritchie E, Cella D, Fabbiano F, et al. The relationship between transfusion status and patient-reported outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL study. Paper presented at the 5th International Conference on Acute Myeloid Leukemia: “Molecular and Translational”: Advances in Biology and Treatment (European School of Hematology); 2019 October 24–26; Estoril, Portugal.
  • Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM. Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia. J Manag Care Spec Pharm. 2021;27(10):1469–1481.
  • Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework [Internet]. Boston (MA): Institute for Clinical and Economic Review; 2020 [cited 2021 May 17]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.